“If you’re an oncologist practicing in a community hospital in Nebraska, how are you possibly going to keep up with all that?” Snow said.
斯诺说:“如果你只是个内布拉斯加州社区医院的肿瘤医生,怎么可能跟得上这些发展呢?”
On the other hand, Flatiron’s “96 percent” statistic is “very deceiving,” Snow said. Most clinical trials won’t accept patients in the early stages of cancer, and even if they do, they typically are looking for a relatively uncommon form of the disease, he said.
而另一方面,斯诺表示,Flatiron公司所谓的“96%”数据也“很唬人”。因为绝大多数临床试验都不会接受早期癌症病人,就算接受,一般也是找那些不太常见的癌症。
“Not every cancer victim is a candidate for clinical trials,” Snow said. “The fact that four percent participate is not a very meaningful statistic.”
斯诺说:“不是每位癌症患者都适合参加临床试验。所谓的4%参与率不是个很有意义的统计数据。”
Compounding the problem: Cancer victims typically don’t know which trials they’re eligible to be in, Snow said. “Even a doctor at Memorial Sloan Kettering may not know what’s going on at Stanford,” he said.
使问题更趋复杂的是:癌症患者一般并不知道自己适合参加哪些临床试验,斯诺称。“就算是斯隆o凯特灵纪念中心(Memorial Sloan Kettering,纽约著名癌症治疗中心——译注)的医生可能也不知道斯坦福大学(Stanford)的研究进展。”
【科技是否万能 大数据能够战胜癌症吗】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15